Clinical ink Announces Strategic Investment from Ardan Equity and GI Partners to Accelerate Next Phase of Growth
Ardan and GI to bring deep, complementary domain expertise across life sciences and healthcare technology and partner with management to further accelerate Clinical ink's growth WINSTON-SALEM, N.C., Oct. 19, 2026 /PRNewswire/ -- Clinical ink, a global clinical trial technology company,...
Read the full story on PR Newswire → Opens the original article on www.prnewswire.comSummary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.